<H1>Chapter DOI: 10.1007/978-1-60327-829-4_13<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>33</td></tr><tr><td>Springer references</td><td>2</td></tr><tr><td>Non Springer references</td><td>31</td></tr><tr><td>BibStructured Count</td><td width="10%">33</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>21</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>0</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>0</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_13</td><td>BibArticle</td><td>Canil CM, Moore MJ, Winquist E, et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2005;23(3):455&#8211;60.</td><td><a href=http://dx.doi.org/10.1200/JCO.2005.02.129>10.1200/JCO.2005.02.129</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2_13</td><td>BibArticle</td><td>Gross M, Higano C, Pantuck A, et al. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 2007;7:142.</td><td><a href=http://dx.doi.org/10.1186/1471-2407-7-142>10.1186/1471-2407-7-142</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3_13</td><td>BibArticle</td><td>Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene 2005;24(50):7465&#8211;74.</td><td><a href=http://dx.doi.org/10.1038/sj.onc.1209096>10.1038/sj.onc.1209096</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4_13</td><td>BibArticle</td><td>Malik SN, Brattain M, Ghosh PM, et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002;8(4):1168&#8211;71.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR5_13</td><td>BibArticle</td><td>Kreisberg JI, Malik SN, Prihoda TJ, et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004;64(15):5232&#8211;6.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-04-0272>10.1158/0008-5472.CAN-04-0272</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6_13</td><td>BibArticle</td><td>Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001;142(11):4795&#8211;805.</td><td><a href=http://dx.doi.org/10.1210/en.142.11.4795>10.1210/en.142.11.4795</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7_13</td><td>BibArticle</td><td>Graff JR, Konicek BW, McNulty AM, et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000;275(32):24500&#8211;5.</td><td><a href=http://dx.doi.org/10.1074/jbc.M003145200>10.1074/jbc.M003145200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8_13</td><td>BibArticle</td><td>Chee KG, Longmate J, Quinn DI, et al. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer 2007;5(7):433&#8211;7.</td><td><a href=http://dx.doi.org/10.3816/CGC.2007.n.031>10.3816/CGC.2007.n.031</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9_13</td><td>BibArticle</td><td>Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271&#8211;81.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa066838>10.1056/NEJMoa066838</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10_13</td><td>BibArticle</td><td>Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004;10(6):594&#8211;601.</td><td><a href=http://dx.doi.org/10.1038/nm1052>10.1038/nm1052</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11_13</td><td>BibArticle</td><td>Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002;62(21):6141&#8211;5.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR12_13</td><td>BibArticle</td><td>Lerut E, Roskams T, Goossens E, et al. Molecular pharmacodynamic (MPD) evaluation of dose and schedule of RAD001 (everolimus) in patients with operable prostate carcinoma (PC). J Clin Oncol (Meeting Abstracts) 2005;23(16_suppl):3071.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR13_13</td><td>BibArticle</td><td>Efstathiou E, Tsavachidou D, Wen S, Troncoso P, Mills GB, Logothetis CJ. Integrated quantative and spatial proteomic analysis of PI3kinase signaling in high grade prostate cancer (PCa) treated with Temsirolimus with or without androgen ablation. J Clin Oncol (Meeting Abstracts) 2008;26(15_suppl):5071.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR14_13</td><td>BibArticle</td><td>O&#8217;Reilly KE, Rojo F, She Q-B, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66(3):1500&#8211;8.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-05-2925>10.1158/0008-5472.CAN-05-2925</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15_13</td><td>BibBook</td><td>George DA, Armstrong AJ, Creel P, et al. A phase II study of RAD001 in men with hormone-refractory metastatic prostate cancer. Proceedings of the Genitourinary Cancers Symposium 2008: Abstract 181.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR16_13</td><td>BibArticle</td><td>Ross RW, Manola J, Oh WK, et al. Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity. J Clin Oncol (Meeting Abstracts) 2008;26(15_suppl):5069.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR17_13</td><td>BibArticle</td><td>Smaletz O, Kelly WK, Horse-Grant D, et al. Epothilone B analogue (BMS-247550) with estramustine phosphate in patients with progressive castrate-metastatic prostate cancer. Proc Am Soc Clin Oncol 2002;21:732.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR18_13</td><td>BibArticle</td><td>Heath EI, Hillman D, Vaishampayan U, et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin (17-AAG) in patients with hormone-refractory metastatic prostate cancer. J Clin Oncol (Meeting Abstracts) 2007;25(18_suppl):15553.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR19_13</td><td>BibArticle</td><td>Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279(5350):563&#8211;6.</td><td><a href=http://dx.doi.org/10.1126/science.279.5350.563>10.1126/science.279.5350.563</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20_13</td><td>BibArticle</td><td>Wu JD, Odman A, Higgins LM, et al. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 2005;11(8):3065&#8211;74.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-04-1586>10.1158/1078-0432.CCR-04-1586</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21_13</td><td>BibArticle</td><td>Krueckl SL, Sikes RA, Edlund NM, et al. increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 2004;64(23):8620&#8211;9.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-04-2446>10.1158/0008-5472.CAN-04-2446</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22_13</td><td>BibArticle</td><td>Kiyama S, Morrison K, Zellweger T, et al. castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 2003;63(13):3575&#8211;84.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR23_13</td><td>BibArticle</td><td>Maulard C, Richaud P, Droz JP, Jessueld D, Dufour-Esquerre F, Housset M. Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 1995;36(3):259&#8211;62.</td><td><a href=http://dx.doi.org/10.1007/BF00685857>10.1007/BF00685857</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24_13</td><td>BibArticle</td><td>Koutsilieris M, Mitsiades CS, Bogdanos J, et al. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clin Cancer Res 2004;10(13):4398&#8211;405.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-04-0077>10.1158/1078-0432.CCR-04-0077</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25_13</td><td>BibArticle</td><td>Ryan CJ, Harzstark AH, Rosenberg J, et al. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int 2008;101(4):436&#8211;9.</td><td><a href=http://dx.doi.org/10.1111/j.1464-410X.2007.07330.x>10.1111/j.1464-410X.2007.07330.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26_13</td><td>BibArticle</td><td>Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007;13(18):5549s&#8211;55s.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-07-1109>10.1158/1078-0432.CCR-07-1109</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27_13</td><td>BibArticle</td><td>Lai M-T, Yang C-C, Lin T-Y, Tsai F-J, Chen W-C. Depsipeptide (FK228) inhibits growth of human prostate cancer cells. Urologic Oncology: Seminars and Original Investigations 2008;26(2):182&#8211;9.</td><td><a href=http://dx.doi.org/10.1016/j.urolonc.2007.01.020>10.1016/j.urolonc.2007.01.020</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28_13</td><td>BibArticle</td><td>Zhang Z, Stanfield J, Frenkel E, Kabbani W, Hsieh J-T. Enhanced therapeutic effect on androgen-independent prostate cancer by depsipeptide (FK228), a histone deacetylase inhibitor, in combination with docetaxel. Urology 2007;70(2):396&#8211;401.</td><td><a href=http://dx.doi.org/10.1016/j.urology.2007.03.052>10.1016/j.urology.2007.03.052</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29_13</td><td>BibArticle</td><td>Parker C, Molife R, Karavasilis V, et al. Romidepsin (FK228), a histone deacetylase inhibitor: final results of a phase II study in metastatic hormone refractory prostate cancer (HRPC). J Clin Oncol (Meeting Abstracts) 2007;25(18_suppl):15507.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR30_13</td><td>&nbsp;</td><td>Early clinical data and potential clinical utility of novel histone deacetylase inhibitors in prostate cancer. Clin Prostate Cancer 2005;4(2):83&#8211;5.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR31_13</td><td>BibArticle</td><td>Marrocco DL, Tilley WD, Bianco-Miotto T, et al. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther 2007;6(1):51&#8211;60.</td><td><a href=http://dx.doi.org/10.1158/1535-7163.MCT-06-0144>10.1158/1535-7163.MCT-06-0144</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32_13</td><td>BibBook</td><td>Bradley DA, Dunn R, Rathkopf D, et al. Vorinostat in hormone refractory prostate cancer (HRPC): trial results and IL-6 analysis. Proceedings of the Genitourinary Cancers Symposium 2008: Abstract 211.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR33_13</td><td>BibArticle</td><td>Rokhlin OW, Glover RB, Guseva NV, Taghiyev AF, Kohlgraf KG, Cohen MB. Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells. Mol Cancer Res 2006;4(2):113&#8211;23.</td><td><a href=http://dx.doi.org/10.1158/1541-7786.MCR-05-0085>10.1158/1541-7786.MCR-05-0085</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>